@entity1143 in XXXX : influence upon clinical course and survival.

@entity1 @entity1143 @entity0 @entity5 @entity3
The clinical course and outcome of 31 @entity1 suffering from @entity0 with documented pleural involvement was reviewed retrospectively. These 31 @entity1 represent 14% of all @entity1 with metastatic @entity0 seen in our Institution between 1977 and 1982. Most effusions were unilateral and ipsilateral to the affected breast, and the median interval from diagnosis of @entity0 to detection of @entity1143 was 32 months (range 0 to 84). In 55% of the @entity1 , the effusion represented the first site of failure; in @entity1 with known @entity3 , the median interval from initial failure to the development of @entity1143 was 12 months. Local recurrence in the affected breast or chest wall very frequently preceded the onset of an ipsilateral effusion. Once pleural fluid developed, spread to other visceral organs was common. Treatment regimens were far from uniform and included systemic chemotherapy, hormone therapy or both, as well as intrapleural treatment; 10 of 22 @entity1 (45%) given any form of therapy other than thoracentesis had a significant decrease in the amount of the effusion, including 3 @entity1 with a complete response. The median survival of all @entity1 from the onset of the effusion was 7 months (1-72); complete responders survived a median of 15 months whereas progressors had a median survival of 5 months only. Prognostic characteristics associated with a prolonged survival were: a unilateral effusion, ipsilateral to the @entity5 ; effusion as first site of relapse, and mainly, an objective response to therapy. Although this is a small series, @entity1 given both systemic and intracavitary treatment achieved best results.(ABSTRACT TRUNCATED AT 250 WORDS)
